Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 7/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28519342 | 0.84 | MLYCD (0.55) | MLYCDCA1CA2HDAC1HDAC6 | |
| SCHEMBL20941564 | 0.84 | MLYCD (0.76) | MLYCDHDAC1HDAC6HDAC7HDAC8 | |
| SCHEMBL19459115 | 0.81 | CES1 (0.56) | MLYCDCES1 | |
| SCHEMBL3976909 | 0.78 | CA2 (0.53) | MLYCDCA1CA2GSK3BPARP15 | |
| SCHEMBL7887114 | 0.78 | CA2 (0.53) | MLYCDCA1CA2GSK3BPARP15 | |
| SCHEMBL1225921 | 0.78 | CA2 (0.53) | MLYCDCA1CA2GSK3BPARP15 | |
| SCHEMBL1467062 | 0.77 | GSK3B (0.56) | MLYCDHDAC1HDAC6CES1GSK3B | |
| SCHEMBL5147851 | 0.76 | PLOD2 (0.64) | MLYCDCA1CA2HDAC1HDAC6 | |
| SCHEMBL27556931 | 0.76 | CA2 (0.61) | MLYCDCA1CA2GSK3BPARP15 | |
| SCHEMBL19056956 | 0.75 | CES1 (0.65) | MLYCDHDAC1HDAC6CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-117164796-A | Cross-linked all-carbon skeleton polymer, anion exchange membrane and preparation method | 宁波中科氢易膜科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-112218857-B | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220331304-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| EP-4003342-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Constellation Pharmaceuticals, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450005-A | Compounds for the treatment of neurological disorders | 星座制药公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-04-22 | — | — | US | disclosed |
| CN-112218857-A | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-3752497-A1 | P300/CBP HAT INHIBITORS | Constellation Pharmaceuticals, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019161162-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0879223-B1 | AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS | CT EUROP DE BIOPROSPECTIVE CEB (FR) | 2001-11-07 | — | — | EP | disclosed |
| US-6265423-B1 | SKIN DISORDERS; ANTICANCER AGENTS | CENTRE EUROPEEN DE BIOPROSPECTIVE-CEB (FR) | 2001-07-24 | — | — | US | disclosed |
| CN-1254335-A | Nicotinamide derivatives | PFIZER PROD INC (US) | 2000-05-24 | — | — | CN | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | MLYCD 2109/4885CA1 4256/4885CA2 4059/4885 |
| US-20220331304-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CLN6, ACHE, NLN | MLYCD 641/4885CA1 380/4885CA2 1124/4885 |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | MLYCD 2109/4885CA1 4256/4885CA2 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.